Changes in motor cortical excitability in schizophrenia following transcranial direct current stimulation

Carregando...
Imagem de Miniatura
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Citação
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.90, p.43-48, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Schizophrenia is a disorder associated with cortical inhibition deficits. Transcranial direct current stimulation (tDCS) induces changes in cortical excitability in healthy subjects and individuals with neuropsychiatric disorders depending on the stimulation parameters. Our aim was to investigate whether a previously published tDCS protocol associated with symptomatic improvement in schizophrenia would induce changes in motor cortical excitability, assessed by transcranial magnetic stimulation paradigms, i.e., short-interval intracortical inhibition (SICI) and intra-cortical facilitation (ICF). We assessed cortical excitability measurements in 48 subjects with schizophrenia before and after a single session of active tDCS (20 min, 2 mA, anode over left dorsolateral prefrontal cortex, cathode over left temporoparietal cortex) or sham. Those who received active tDCS had a significant increase of SICI in the left motor cortex compared to those who received sham stimulation (Cohen's d = 0.54, p = .019). No changes were observed for ICF. In addition, lower SICI was associated with higher age (beta = -0.448, p < .01). Increase in intracortical inhibition may indicate a mechanism of action of tDCS in this population. Future studies should investigate whether this finding is a biomarker of treatment response for schizophrenia.
Palavras-chave
Schizophrenia, Negative symptoms, Cortical excitability, Transcranial magnetic stimulation, Transcranial direct current stimulation
Referências
  1. Akbarian S, 2006, BRAIN RES REV, V52, P293, DOI 10.1016/j.brainresrev.2006.04.001
  2. Andreasen NC, 2010, BIOL PSYCHIAT, V67, P255, DOI 10.1016/j.biopsych.2009.08.040
  3. ANDREASEN NC, 1989, BRITISH JOURNAL OF PSYCHIATRY, VOL 155, SUPP NO. 7, P49
  4. Antal A, 2017, CLIN NEUROPHYSIOL, V128, P1774, DOI 10.1016/j.clinph.2017.06.001
  5. Bajbouj M, 2006, BIOL PSYCHIAT, V59, P395, DOI 10.1016/j.biopsych.2005.07.036
  6. Bartels-Velthuis AA, 2012, EPIDEMIOL PSYCH SCI, V21, P305, DOI 10.1017/S2045796012000108
  7. Biabani M, 2018, REV NEUROSCIENCE, V29, P99, DOI 10.1515/revneuro-2017-0023
  8. Bikson M, 2018, BRAIN STIMUL, V11, P465, DOI 10.1016/j.brs.2017.12.008
  9. Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004
  10. Borckardt JJ, 2012, J PAIN, V13, P112, DOI 10.1016/j.jpain.2011.07.001
  11. Brunelin J, 2012, AM J PSYCHIAT, V169, P719, DOI 10.1176/appi.ajp.2012.11071091
  12. Brunoni AR, 2013, EUR PSYCHIAT, V28, P356, DOI 10.1016/j.eurpsy.2012.09.001
  13. Brunoni Andre R, 2018, Braz J Psychiatry, DOI 10.1590/1516-4446-2017-0018
  14. Chang CC, 2018, INT J NEUROPSYCHOPH, V21, P979, DOI 10.1093/ijnp/pyy074
  15. Chong HY, 2016, NEUROPSYCH DIS TREAT, V12, P357, DOI 10.2147/NDT.S96649
  16. Cueva AS, 2016, NEUROPHYSIOL CLIN, V46, P43, DOI 10.1016/j.neucli.2015.12.003
  17. Daskalakis ZJ, 2008, J PSYCHOPHARMACOL, V22, P203, DOI 10.1177/0269881107084002
  18. Daskalakis ZJ, 2002, ARCH GEN PSYCHIAT, V59, P347, DOI 10.1001/archpsyc.59.4.347
  19. Di Lazzaro V, 2006, J NEUROPHYSIOL, V96, P1765, DOI 10.1152/jn.00360.2006
  20. Di Lazzaro V, 2005, J PHYSIOL-LONDON, V564, P661, DOI 10.1113/jphysiol.2004.061747
  21. Fitzgerald PB, 2004, SCHIZOPHR RES, V71, P17, DOI 10.1016/j.schres.2004.01.018
  22. Frantseva MV, 2008, CEREB CORTEX, V18, P990, DOI 10.1093/cercor/bhm151
  23. Frohlich F, 2016, EUR PSYCHIAT, V33, P54, DOI 10.1016/j.eurpsy.2015.11.005
  24. Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003
  25. Gordon PC, 2018, BRAIN STIMUL, V11, P1024, DOI 10.1016/j.brs.2018.06.004
  26. Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010
  27. Hasan Alkomiet, 2013, Front Psychiatry, V4, P121, DOI 10.3389/fpsyt.2013.00121
  28. Hasan A, 2011, BEHAV BRAIN RES, V224, P15, DOI 10.1016/j.bbr.2011.05.017
  29. Hasenstaub A, 2005, NEURON, V47, P423, DOI 10.1016/j.neuron.2005.06.016
  30. Hill AT, 2017, NEUROIMAGE, V152, P142, DOI 10.1016/j.neuroimage.2017.03.001
  31. Hoftman GD, 2018, BIOL PSYCHIAT, V83, P670, DOI 10.1016/j.biopsych.2017.11.029
  32. Hu H, 2014, SCIENCE, V345, P529, DOI 10.1126/science.1255263
  33. Kaster TS, 2015, SCHIZOPHR RES, V165, P157, DOI 10.1016/j.schres.2015.04.015
  34. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
  35. Kennedy NI, 2018, EUR PSYCHIAT, V49, P69, DOI 10.1016/j.eurpsy.2017.12.025
  36. KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912
  37. Kuo HI, 2013, BRAIN STIMUL, V6, P644, DOI 10.1016/j.brs.2012.09.010
  38. Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087
  39. Lewis DA, 1999, BIOL PSYCHIAT, V46, P616, DOI 10.1016/S0006-3223(99)00061-X
  40. Liu SK, 2009, BIOL PSYCHIAT, V65, P503, DOI 10.1016/j.biopsych.2008.09.012
  41. McLaren ME, 2018, BRAIN STIMUL, V11, P52, DOI 10.1016/j.brs.2017.10.006
  42. Minzenberg MJ, 2009, ARCH GEN PSYCHIAT, V66, P811, DOI 10.1001/archgenpsychiatry.2009.91
  43. Mondino M, 2016, SCHIZOPHRENIA BULL, V42, P318, DOI 10.1093/schbul/sbv114
  44. MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
  45. Narita Z, 2018, J PSYCHIATR RES, V103, P5, DOI 10.1016/j.jpsychires.2018.05.004
  46. Peinemann A, 2001, NEUROSCI LETT, V313, P33, DOI 10.1016/S0304-3940(01)02239-X
  47. Radhu N, 2013, CLIN NEUROPHYSIOL, V124, P1309, DOI 10.1016/j.clinph.2013.01.014
  48. Rawji V, 2018, BRAIN STIMUL, V11, P289, DOI 10.1016/j.brs.2017.11.001
  49. Remington G., 2016, CURR TREAT OPTIONS P, V3, P133, DOI [10.1007/s40501-016-0075-8, DOI 10.1007/S40501-016-0075-8]
  50. Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016
  51. Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001
  52. Sarkar S, 2015, WORLD J PSYCHIATR, V5, P352, DOI 10.5498/wjp.v5.i4.352
  53. Smith RC, 2015, SCHIZOPHR RES, V168, P260, DOI 10.1016/j.schres.2015.06.011
  54. Strube W, 2016, BEHAV BRAIN RES, V311, P46, DOI 10.1016/j.bbr.2016.05.027
  55. Valiengo L, 2018, BIOL PSYCHIAT, V83, pS207, DOI 10.1016/j.biopsych.2018.02.541
  56. Wobrock T, 2009, PHARMACOPSYCHIATRY, V42, P194, DOI 10.1055/s-0029-1224137
  57. Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734
  58. Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028